New MS biosimilar PB018 faces first human test against ocrevus
NCT ID NCT07606521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial will test PB018, a biosimilar to the MS drug Ocrevus, in 222 people with multiple sclerosis. The study compares how the body processes PB018 versus Ocrevus and checks for safety. Participants will receive either PB018 or Ocrevus, but neither they nor their doctors will know which one. The goal is to see if PB018 behaves similarly in the body, which could lead to a more affordable treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PB018 (a biosimilar to ocrelizumab)
What this could lead to
If successful, PB018 could offer a more affordable treatment option for multiple sclerosis, similar to Ocrevus.
What could go wrong
This is an early Phase 1 trial focused on drug levels and safety, not on effectiveness. The biosimilar may not work as well or have different side effects than Ocrevus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.